Primary extremity soft tissue sarcomas: Outcome improvement over time at a single institution

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1675-1681

  Gronchi, A ^a   Miceli, R ^a   Colombo, C ^a   Collini, P ^a   Stacchiotti, S ^a   Olmi, P ^a   Mariani, L ^a   Bertulli, R ^a   Fiore, M ^a   Casali, P G ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; Prognosis; Radiotherapy; Sarcoma; Surgery; Treatment outcome

Indexed keywords

ANTHRACYCLINE; IFOSFAMIDE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS POTENTIAL; MYXOSARCOMA; NERVE SHEATH TUMOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; SURVIVAL TIME; SYNOVIAL SARCOMA; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 79959746009     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq643     Document Type: Article

References (36)

1. Pisters PWT, Leung DH, Woodruff J et al. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996; 14: 1679-1689.
2. Stojadinovic A, Leung DH, Hoos A et al. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 2002; 235: 424-434.
3. Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma specific death. J Clin Oncol 2002; 20: 791-796.
4. Gronchi A, Casali PG, Mariani L et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 2005; 23: 96-104.
5. Mariani L, Miceli R, Kattan MW et al. Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. Cancer 2005; 103: 402-408.
6. Coindre JM, Terrier P, Bui NB et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996; 14: 869-877.
7. Rosenberg SA, Tepper J, Glatstein E et al. The treatment of soft-tissue sarcomas of the extremities. Ann Surg 1982; 196: 305-315.
8. Pisters PWT, Harrison LB, Leung DH et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy on soft tissue sarcoma. J Clin Oncol 1996; 14: 859-868.
9. Yang JC, Chang AE, Baker AR et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998; 16: 197-203.
10. Gronchi A, Miceli R, Fiore M et al. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. Ann Surg Oncol 2007; 14(5): 1583-1590.
11. Pisters PWT, O'Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol 2007; 25: 1003-1008.
12. Gronchi A, Olmi P, Casali PG. Combined modalities approach to localized adult extremity soft tissue sarcoma. Expert Rev Anticancer Ther 2007; 7(8): 1135-1144.
13. Wunder JS, Nielsen TO, Maki RG et al. Opportunities for improving the therapeutic ration for patients with sarcoma. Lancet Oncol 2007; 8(6): 513-524.
14. Verweij J, Baker LH. Future treatment of soft tissue sarcoma will be driven by histological subtype and molecular aberrations. Eur J Cancer 2010; 46(5): 863-868.
15. Trojani M, Contesso G, Coindre JM et al. Soft tissue sarcomas of adults: study of pathological prognostic variables and definition of a histopathologic grading system. Int J Cancer 1984; 33: 37-42.
16. Marubini E, Valsecchi MG. Analysing Survival Data for Clinical Trials and Observational Studies. Chichester, UK: John Wiley and Sons 1995.
17. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
18. Trovik CS, Bauer HC, Alvegard TA et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 2000; 36(6): 710-716.
19. Kraybill WG, Harris J, Spiro JJ et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, highgrade soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006; 24(4): 619-625.
20. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med 1989; 8: 551-561.
21. Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312(25): 1604-1608.
22. O'Sullivan B, Davis AM, Turcotte R et al. Preoperative versus postoperative radiotherapy in soft tissue sarcoma of the limbs: a randomised trial. Lancet 2002; 359: 2235-2241.
23. Eilber FC, Rosen G, Nelson SD et al. High-grade extremity soft tissue sarcomas: factors predictive of local recurrence and its effect on morbidity and mortality. Ann Surg 2003; 237: 218-226.
24. Pollack A, Zagars GK, Goswitz MS et al. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys 1998; 42: 563-572.
25. Zagars GK, Ballo MT, Pisters PWT et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy. Cancer 2003; 97: 2530-2543.
26. Weitz J, Antonescu CR, Brennan MF. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003; 21: 2719.
27. Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001; 19: 1238-1247.
28. Woll PJ, Van Glabbeke M, Hohenberger P et al. Adjuvant chemotherapy with doxorubicine and ifosfamide in resected soft tissue sarcoma: interim analysis of a phase III trial. J Clin Oncol 2007; 25(18s): 1008.
29. Pervaiz N, Colterjohn N, Farrokhiar F et al. A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft tissue sarcoma. Cancer 2008; 113(3): 573-581.
30. Jaffe N. Adjuvant chemotherapy in osteosarcoma: an odyssey of rejection and vindication. Cancer Treat Res 2010; 152: 219-237.
31. Brennan MF. Local recurrence in soft tissue sarcoma: more about the tumor, less about the surgeon. Ann Surg Oncol 2007; 14(5): 1528-1529.
32. Gronchi A, Lo Vullo S, Colombo C et al. Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 2010; 251: 512-517.
33. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8(7): 595-602.
34. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007; 25(19): 2755-2763.
35. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26(32): 5269-5274.
36. Krikelis D, Judson I. Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther 2010; 10(2): 249-260.